To view the presentation of the preliminary results for the year ended 31 March 2020 please click here.
To view the presentation of the preliminary results for the year ended 31 March 2020 please click here.
20 July 2020: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2020.
17 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, provides the following update on its cell-based therapy programmes.
10 September 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of the Company’s Annual General Meeting (“AGM”) this Thursday.
8 May 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces a year-end business update ahead of its preliminary results for the year ended 31 March 2019, which will be announced on Thursday 11 July 2019.
To view the full article click here…
To view the full article click here…
5th June 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a further update regarding its US clinical and regulatory development strategy for its CTX cell therapy candidate for stroke disability.